Subsection 1: Tasks

I.-The national register mentioned in 4° of Article R. 1418-1 comprises three files:

1° The file relating to voluntary donors of haematopoietic stem cells and peripheral blood mononuclear cells;

2° The file relating to placental blood units;

3° The file relating to patients awaiting a haematopoietic stem cell transplant in France or abroad.

II - The Agency is responsible for

1° Managing the national register of voluntary donors of haematopoietic stem cells and peripheral blood mononuclear cells and the national register of placental blood units;

2° Registering national and foreign patients for whom an unrelated haematopoietic stem cell transplant has been indicated;

3° Searching for haematopoietic stem cells from France or abroad and making them available to French and foreign transplant teams.

III - In application of II, the Agence de la biomédecine sets :

1° Under 1° and 2°, the fee for access by French transplant teams to the national file and to the international donor and placental blood unit files;

2° Under 3°, the fees for services enabling haematopoietic stem cells, peripheral blood mononuclear cells or placental blood units to be made available to French or foreign transplant teams, as well as, where applicable, the amount of management fees corresponding to the provision of these cells or units.

IV - In order to carry out the activities mentioned in II, the Agency coordinates the action of the establishments or organisations which, on a voluntary basis, participate in the information, selection, registration and management of voluntary donors of haematopoietic stem cells and blood mononuclear cells on the file mentioned in 1° of I as well as the action of those who participate in the registration of placental blood units on the file mentioned in 2° of I.

These establishments or organisations participate in these activities within the framework of protocols established by the Agence de la biomédecine.

These protocols mention :

1° All the rules with which these establishments or organisations must comply in application of ethical principles, in particular those relating to donation, confidentiality and the protection of data relating to the donor or the placental blood unit;

2° The fixed amount of compensation proposed to the establishments or organisations mentioned in the first paragraph of this IV. This amount may change depending, in particular, on developments in HLA typing techniques.